SLN Silence Therapeutics PLC Total Business Assets

Silence Therapeutics is developing high-precision drugs to combat blood and heart pathologies, leveraging mRNA interference technology. Growth for the company is driven by licensing payments from pharma behemoths and positive trial results for its siRNA platform. The price history of total assets on GURU.Markets shows a value of 135.82. AI and robotics have been implemented in production, although the final data assessment remains with the experts.

Assessing the margin of safety for Silence Therapeutics (SLN) requires an analysis of its material base. Total assets, calculated inversely via ROA, aggregate equity and liabilities to determine the actual scale of the business. The dynamics of the company's total resources allow for tracking the development vector and avoiding buying at the peak of the trend. Current growth is supported by the success of the small RNA platform, whose clinical tests form the foundation for the upcoming Phase III.